US 12,065,463 B2
Compositions and methods for treating CNS disorders
Gabriel Martinez Botella, Wayland, MA (US); Francesco G. Salituro, Marlborough, MA (US); Albert Jean Robichaud, Boston, MA (US); and Boyd L. Harrison, Princeton Junction, NJ (US)
Assigned to Sage Therapeutics, Inc., Cambridge, MA (US)
Filed by Sage Therapeutics, Inc., Cambridge, MA (US)
Filed on Oct. 24, 2022, as Appl. No. 17/971,865.
Application 17/971,865 is a continuation of application No. 16/748,117, filed on Jan. 21, 2020, granted, now 11,530,237.
Application 16/748,117 is a continuation of application No. 16/206,472, filed on Nov. 30, 2018, abandoned.
Application 16/206,472 is a continuation of application No. 15/519,480, granted, now 10,577,390, issued on Mar. 3, 2020, previously published as PCT/US2015/056054, filed on Oct. 16, 2015.
Claims priority of provisional application 62/064,961, filed on Oct. 16, 2014.
Prior Publication US 2023/0113666 A1, Apr. 13, 2023
Int. Cl. A61K 31/58 (2006.01); A61K 31/575 (2006.01); A61K 45/06 (2006.01); C07J 9/00 (2006.01); C07J 43/00 (2006.01); C07J 1/00 (2006.01); C07J 3/00 (2006.01); C07J 5/00 (2006.01); C07J 7/00 (2006.01); C07J 11/00 (2006.01); C07J 13/00 (2006.01); C07J 21/00 (2006.01); C07J 31/00 (2006.01); C07J 41/00 (2006.01); C07J 51/00 (2006.01); C07J 71/00 (2006.01)
CPC C07J 43/003 (2013.01) [A61K 31/575 (2013.01); A61K 31/58 (2013.01); A61K 45/06 (2013.01); C07J 9/00 (2013.01); C07J 1/0011 (2013.01); C07J 1/0022 (2013.01); C07J 3/005 (2013.01); C07J 5/0053 (2013.01); C07J 7/002 (2013.01); C07J 7/007 (2013.01); C07J 7/008 (2013.01); C07J 11/00 (2013.01); C07J 13/007 (2013.01); C07J 21/00 (2013.01); C07J 31/006 (2013.01); C07J 41/0066 (2013.01); C07J 51/00 (2013.01); C07J 71/001 (2013.01)] 2 Claims
 
1. A compound of the formula

OG Complex Work Unit Chemistry